Pharmacodynamic analysis of the analgesic effect of capsaicin 8% patch (Qutenza™) in diabetic neuropathic pain patients: Detection of distinct response groups

Journal of Pain Research

Volumn 5, Issue , 2012, Pages 51-59

  Martini, Christian ^a   Yassen, Ashraf ^b   Olofsen, Erik ^a   Passier, Paul ^b   Stoker, Malcom ^b   Dahan, Albert ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Astellas Pharma Global Development   (Netherlands)

Author keywords

Capsaicin 8 ; Diabetic neuropathic pain; Mixture model; Modeling

Indexed keywords

CAPSAICIN;

ACCURACY; ADULT; AGED; ARTICLE; BEHAVIOR CHANGE; CONTROLLED STUDY; DIABETIC NEUROPATHY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL COMPUTING; MATHEMATICAL MODEL; MULTICENTER STUDY; NEUROPATHIC PAIN; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PATIENT ASSESSMENT; PROCESS DEVELOPMENT; RANDOMIZED CONTROLLED TRIAL; TRANSDERMAL PATCH;

EID: 84874938328     PISSN: 11787090     EISSN: None     Source Type: Journal    
DOI: 10.2147/JPR.S30406     Document Type: Article

References (23)

1. Spruce MC, Potter J, Coppini DV. The pathogenesis and management of painful diabetic neuropathy: a review. Diabetic Med. 2002;20: 88-98.
2. Dyck PJ, Giannini C. Pathologic alterations in the diabetic neuropathies of humans: a review. J Neuropathol Exp Neurol. 1996;55:1181-1193.
3. Vinik AI. Advances in diabetes for the millennium: new treatments for diabetic neuropathies. Med Gen Med. 2004;(Suppl 6):13.
4. Baron R, Tölle TR, Gockel U, Brosz M, Freynhagen R. A cross-sectional cohort survey in 2100 patients with painful diabetic neuropathy and postherpetic neuralgia: Differences in demographic data and sensory symptoms. Pain. 2009;146:34-40.
5. Backonja M, Beydoun A, Edwards KR, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus. JAMA. 1998;280:1831-1836.
6. Koltzenburg M. Painful neuropathies. Curr Opinion Neurol. 1999;11: 515-521.
7. Anand P, Bley K. Topical capsaicin for pain management: Therapeutical potential and mechanisms of action of the new high-concentration capsaicin 8% patch. Br J Anaesth. 2011;107:490-502.
8. Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature. 1997;389:816-824.
9. Szallasi A, Blumberg PM. Vanilloid (capsaicin) receptors and mechanisms. Pharmacol Rev. 1999;51:159-211.
10. Tominaga M, Caterina MJ, Malmberg AB, et al. The cloned capsaicin receptor integrates multiple pain-producing stimuli. Neuron. 1998;21:531-543.
11. Nolano M, Simone DA, Wendelschafer-Crabb G, Johnson T, Hazen E, Kennedy WR. Topical capsaicin in humans: parallel loss of epidermal nerve fibers and pain sensation. Pain. 1999;81:135-145.
12. Simone DA, Ochoa J. Early and late effects of prolonged topical capsaicin on cutaneous sensibility and neurogenic vasodilation in humans. Pain. 1991;47:285-294.
13. Webster LR, Peppin JF, Murphy FT, Lu B, Tobias JK, Vanhove GF. Efficacy, safety, and tolerability of NGX-4010, capsaicin 8% patch, in an open-label study of patients with peripheral neuropathic pain. Diabetes Res Clin Prac. 2011;93:187-197.
14. Beal BL, Sheiner LB, Boeckman AJ, Bauer RJ. NONMEM User's Guide. Ellicott City, MD: Icon Development Solutions; 2009.
15. Christakis NA. Does this work for you? To say a drug "works" is only half the story. Brit Med J. 2008;337:1025.
16. Wolfe GI, Barohn RJ. Painful peripheral neuropathy. Curr Treat Options Neurol. 2002;4:177-188.
17. Sigtermans M, van Hilten JJ, Bauer MCR, et al. Ketamine produces effective and long-term pain relief in patients with complex regional pain syndrome type 1. Pain. 2009;145:304-311.
18. Dahan A, Olofsen E, Sigtermans M, et al. Population pharmacokineticpharmacodynamic modeling of ketamine-induced pain relief in chronic pain. Eur J Pain. 2001;15:258-267.
19. Yassen A, Olofsen E, Kan J, Dahan A, Danhof M. Pharmacokineticpharmacodynamic modeling of the effectiveness and safety of buprenorphine and fentanyl in rats. Pharm Res. 2008;25:183-193.
20. Zanderigo E, Sartori V, Sveticic G, et al. The well-being model: a new drug interaction model for positive and negative effects. Anesthesiology. 2006;104:742-755.
21. Lunn MPT, Hughes RAC, Wiffen PJ. Duloxetin for treating painful neuropathy or chronic pain. Cochrane Database Syst Rev. 2009;4: CD007115.
22. Moore RA, Straube S, Wiffen PJ, Derry S, McQuay HJ. Pregabalin for acute and chronic pain in adults. Cochrane Database Syst Rev. 2009;3: CD007076.
23. Moore RA, Wiffen PJ, Derry S, McQuay HJ. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2011;3:CD007938.